Related Experiment Videos
Increased incidence of pneumococcal bloodstream infections
Marta Rodríguez-Créixems1, Juan Bertó, Patricia Muñoz
1Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Insights
Pneumococcal bloodstream infections significantly increased in children between 1986 and 2000. The heptavalent vaccine covers most serogroups responsible for these infections.
Area of Science:
- Pediatric Infectious Diseases
- Epidemiology
- Vaccinology
Background:
- Pneumococcal bloodstream infections (PBSI) pose a significant threat to pediatric populations.
- Surveillance data from 1986-2000 indicated a concerning rise in PBSI incidence.
- Understanding trends in PBSI is crucial for public health interventions.
Purpose of the Study:
- To analyze the incidence trends of pneumococcal bloodstream infections in pediatric patients.
- To assess the potential impact of the heptavalent pneumococcal conjugate vaccine on PBSI rates.
Main Methods:
- Retrospective analysis of PBSI cases in a defined population (approx. 650,000 inhabitants).
- Calculation of incidence rates per 100,000 population, stratified by age groups.
- Comparison of incidence rates between 1986 and 2000.
Main Results:
- Overall PBSI incidence in pediatric patients rose from 3.6 to 14.8 episodes per 100,000.
- Incidence in children under 24 months increased dramatically from 7.4 to 78.6 episodes per 100,000 per year.
- The new heptavalent vaccine encompasses 75% of the identified serogroups.
Conclusions:
- There was a substantial increase in pediatric pneumococcal bloodstream infections from 1986 to 2000.
- The findings highlight the need for effective prevention strategies, such as vaccination.
- The heptavalent vaccine's coverage of major serogroups offers a promising tool to combat PBSI.
Abstract:
Pneumococcal bloodstream infections in pediatric patients rose from 3.6 to 14.8 episodes per 100,000 from 1986 to the year 2000 (P < 0.001) in a population of approximately 650,000 inhabitants (16% <16 years of age). Incidence in the group <24 months of age increased from 7.4 to 78.6 episodes per 100,000 per year (P < 0.001). Overall 75% of the serogroups are included in the new heptavalent vaccine.